Seroprevalence of HBV and HCV in Primary Hepatocellular Carcinoma Patients in Zimbabwe

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2009 Oct 10

PMID 19814789

Citations 6

Authors

Nyasha Chinombe

Evans Chavhunduka

Hilda T Matarira

Affiliations

Soon will be listed here.

Abstract

Background: Primary hepatocellular carcinoma (PHC) is one of the most common cancers in Zimbabwe. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are suspected to play a major role in causing this cancer. The objective of this study was to determine the seroprevalence of HBV and HCV in PHC at Parirenyatwa Referral Hospital in Zimbabwe. We evaluated the serological markers of the two viruses in patients with PHC using commercially available enzyme-linked immunosorbent kits.

Results: Out of the 60 patients with PHC, 48.3% were seropositive for HBV and 20.0% were seropositive for HCV. Co-infection by HCV and HBV was found in 8% of the patients. Only 13.3% of the health controls (blood donors) were positive for HBV. All the controls were negative for HCV.

Conclusion: The high seropositivity of HBV and HCV in PHC in Zimbabwe suggested that the two viruses were a major cause of the cancer.

Citing Articles

Seroprevalence of hepatitis B and C viruses and some possible associated factors among cancer patients at the Oncology Treatment Center, Gondar, Northwest Ethiopia: A cross-sectional study.

Atanaw T, Girmay G, Zemene A, Assefa M, Eshetie T, Bewket G PLoS One. 2024; 19(8):e0308161.

PMID: 39093829 PMC: 11296633. DOI: 10.1371/journal.pone.0308161.

Demographic Profile and Etiology of Hepatocellular Carcinoma in Zaria, Northern Nigeria.

Manko M, Mohammed M, Ahmed M, Bello A, Egbegbedia P, Abdullahi U Niger Med J. 2024; 63(4):282-287.

PMID: 38863473 PMC: 11163258. DOI: 10.60787/NMJ-63-4-74.

Prevalence and trends of hepatitis B and C virus biomarkers in Zimbabwe: comparative analyses of a nation's blood-donor surveillance data and meta-analyses of population studies.

Mabaya S, Munongo E, Mapako T, Marowa L, Gasasira A, Pasipanodya J Infect Dis (Lond). 2024; 56(9):759-775.

PMID: 38743051 PMC: 11575482. DOI: 10.1080/23744235.2024.2351045.

Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.

Mbaga D, Kenmoe S, Kengne-Nde C, Ebogo-Belobo J, Mahamat G, Rodrigue Foe-Essomba J PLoS One. 2022; 17(1):e0262903.

PMID: 35061846 PMC: 8782350. DOI: 10.1371/journal.pone.0262903.

Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.

Dzingirai B, Katsidzira L, Matyanga C, Postma M, van Hulst M, Mafirakureva N J Viral Hepat. 2021; 28(7):994-1002.

PMID: 33797190 PMC: 8252795. DOI: 10.1111/jvh.13510.

References

Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm S, Christensen E . Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97(11):2886-95. DOI: 10.1111/j.1572-0241.2002.07057.x. View

Barth H, Liang T, Baumert T . Hepatitis C virus entry: molecular biology and clinical implications. Hepatology. 2006; 44(3):527-35. DOI: 10.1002/hep.21321. View

Webster G, Barnes E, Brown D, Dusheiko G . HCV genotypes--role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14(2):229-40. DOI: 10.1053/bega.1999.0072. View

Liaw Y, Chu C . Hepatitis B virus infection. Lancet. 2009; 373(9663):582-92. DOI: 10.1016/S0140-6736(09)60207-5. View

Lok A . Chronic hepatitis B. N Engl J Med. 2002; 346(22):1682-3. DOI: 10.1056/NEJM200205303462202. View

Fattovich G, Bortolotti F, Donato F . Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2007; 48(2):335-52. DOI: 10.1016/j.jhep.2007.11.011. View

Chen C, Yang H, Su J, Jen C, You S, Lu S . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73. DOI: 10.1001/jama.295.1.65. View

Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I . Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998; 28(6):930-8. DOI: 10.1016/s0168-8278(98)80339-5. View

Shepard C, Finelli L, Alter M . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67. DOI: 10.1016/S1473-3099(05)70216-4. View

10.

Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G . Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000; 89(1):53-9. View

11.

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View

12.

Kew M, Houghton M, Choo Q, Kuo G . Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet. 1990; 335(8694):873-4. DOI: 10.1016/0140-6736(90)90474-j. View

13.

Nyathi C, Mutiro C, Hasler J, Chetsanga C . Human exposure to aflatoxins in Zimbabwe. Cent Afr J Med. 1989; 35(12):542-5. View

14.

Gangaidzo I, Moyo V, Khumalo H, Saungweme T, Gomo Z, Rouault T . Hepatitis C virus in Zimbabwe. Cent Afr J Med. 1997; 43(5):122-5. View

15.

Parkin D, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H . Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol. 2008; 9(7):683-92. DOI: 10.1016/S1470-2045(08)70175-X. View

16.

Malik A, Lee W . Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med. 2000; 132(9):723-31. DOI: 10.7326/0003-4819-132-9-200005020-00007. View

17.

Lavanchy D . Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2006; 34 Suppl 1:S1-3. DOI: 10.1016/s1386-6532(05)00384-7. View

18.

Dusheiko G . The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepat. 1998; 5 Suppl 1:9-12. DOI: 10.1046/j.1365-2893.1998.0050s1009.x. View

19.

Fattovich G, Stroffolini T, Zagni I, Donato F . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1):S35-50. DOI: 10.1053/j.gastro.2004.09.014. View

20.

Trevisani F, DIntino P, Grazi G, Caraceni P, Gasbarrini A, Colantoni A . Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. Cancer. 1996; 77(11):2223-32. DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2223::AID-CNCR7>3.0.CO;2-Q. View